Ameriprise Financial Inc Ultragenyx Pharmaceutical Inc. Transaction History

Ameriprise Financial Inc

$381 Billion
Q3 2024

A detailed history of Ameriprise Financial Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 12,357 shares of RARE stock, worth $530,609. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,357

Previous 11,779 4.91%

Holding current value

$530,609

Previous $484,000 41.74%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $23,241 - $34,310	578 Added 4.91%	12,357 $686,000
Q2 2024 Aug 14, 2024	SELL	$37.42 - $51.61 $70,686 - $97,491	-1,889 Reduced 13.82%	11,779 $484,000
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $111,507 - $139,164	2,592 Added 23.4%	13,668 $638,000
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $140,151 - $217,272	-4,417 Reduced 28.51%	11,076 $529,000
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $182,526 - $243,891	-5,227 Reduced 25.23%	15,493 $552,000
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $1.41 Million - $1.97 Million	-37,775 Reduced 64.58%	20,720 $955,000
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $751,340 - $989,397	20,312 Added 53.2%	58,495 $2.35 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $744,942 - $1.02 Million	22,092 Added 137.29%	38,183 $1.77 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $60,259 - $99,739	1,508 Added 10.34%	16,091 $667,000
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $458 - $854	10 Added 0.07%	14,583 $870,000
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $21,521 - $29,202	-346 Reduced 2.32%	14,573 $1.06 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $16,511 - $19,680	224 Added 1.52%	14,919 $1.26 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $807,640 - $1.06 Million	-10,365 Reduced 41.36%	14,695 $1.33 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $78,177 - $98,122	848 Added 3.5%	25,060 $2.39 Million
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $1.79 Million - $2.8 Million	-16,714 Reduced 40.84%	24,212 $2.76 Million
Q4 2020 Feb 12, 2021	BUY	$84.4 - $177.39 $1.5 Million - $3.15 Million	17,730 Added 76.44%	40,926 $5.67 Million
Q3 2020 Nov 16, 2020	BUY	$72.98 - $90.0 $257,546 - $317,610	3,529 Added 17.94%	23,196 $1.91 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $301,162 - $502,172	-6,420 Reduced 24.61%	19,667 $1.54 Million
Q1 2020 May 15, 2020	BUY	$33.8 - $62.9 $562,263 - $1.05 Million	16,635 Added 175.99%	26,087 $1.16 Million
Q4 2019 Feb 14, 2020	SELL	$36.08 - $45.83 $32.2 Million - $40.9 Million	-892,376 Reduced 98.95%	9,452 $402,000
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $671,372 - $996,948	-15,797 Reduced 1.72%	901,828 $38.6 Million
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $4.94 Million - $6.68 Million	89,865 Added 10.86%	917,625 $58.3 Million
Q1 2019 May 15, 2019	SELL	$39.87 - $69.36 $746,047 - $1.3 Million	-18,712 Reduced 2.21%	827,760 $57.4 Million
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $15 Million - $29.8 Million	-385,801 Reduced 31.31%	846,472 $36.8 Million
Q3 2018 Nov 14, 2018	SELL	$71.81 - $90.15 $7.12 Million - $8.94 Million	-99,189 Reduced 7.45%	1,232,273 $94.1 Million
Q2 2018 Aug 14, 2018	BUY	$48.54 - $85.31 $6.43 Million - $11.3 Million	132,431 Added 11.04%	1,331,462 $102 Million
Q1 2018 May 15, 2018	BUY	$44.33 - $58.52 $51.5 Million - $68 Million	1,161,985 Added 3136.6%	1,199,031 $61.1 Million
Q4 2017 Feb 12, 2018	SELL	$43.54 - $57.32 $414,370 - $545,514	-9,517 Reduced 20.44%	37,046 $1.72 Million
Q3 2017 Nov 07, 2017	BUY	$49.79 - $66.32 $2.32 Million - $3.09 Million	46,563	46,563 $2.48 Million

Others Institutions Holding RARE

# of Institutions

324

Shares Held

85.5M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Ultragenyx Pharmaceutical Inc. Transaction History